| Bioactivity | Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3]. |
| In Vivo | Sotalol is an antiarrhythmic agent.Sotalol at doses of up to 100 mg/kg does not affect the electroconvulsive threshold. Applied at doses of 80-100 mg/kg, sotalol does not affect the antielectroshock action of Oxcarbazepine, Lamotrigine, Pregabalin, or Topiramate. Sotalol alone and in combinations with antiepileptics impairs neither motor performance nor long-term memory. Sotalol (100 mg/kg) significantly decreases the brain concentration of Lamotrigine, increases those of Oxcarbazepine and Topiramate, and does not affect the level of Pregabalin[3]. Animal Model: |
| Name | Sotalol |
| CAS | 3930-20-9 |
| Formula | C12H20N2O3S |
| Molar Mass | 272.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Marta Reyes-Corral, et al. Differential Free Intracellular Calcium Release by Class II Antiarrhythmics in Cancer Cell Lines. J Pharmacol Exp Ther. 2019 Apr;369(1):152-162. [2]. Xiaomei Li, et al. Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia. Pediatr Cardiol. 2017 Oct;38(7):1450-1455. [3]. Kinga K Borowicz-Reutt, et al. Sotalol does not interfere with the antielectroshock action of selected second-generation antiepileptic drugs in mice.Pharmacol Rep. 2021 Apr;73(2):516-524. |